Tech Company Inital Public Offerings
Bolt Biotherapeutics IPO
On 2/5/2021, Bolt Biotherapeutics became a public company.
Transaction Overview
Company Name
Announced On
2/5/2021
Transaction Type
IPO
Amount
$230,000,000
Proceeds Purpose
We currently expect to use our net proceeds from this offering as follows: to fund the clinical development of BDC-1001 for the treatment of four distinct groups of patients with HER2-expressing cancers through completion of our existing Phase 1/2 clinical trial; to fund completion of IND-enabling studies, chemistry, manufacturing and control, or CMC, activities and the clinical development of our CEA Boltbody ISAC program; and the remaining proceeds for PD-L1 Boltbody ISAC program, research and development activities, as well as working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
640 Galveston Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a private biotechnology company developing Boltbody Immune-stimulating Antibody Conjugates (ISAC), a new class of cancer therapeutics. These systemically-administered, tumor-targeted Boltbody therapeutics unleash the immune system to induce anti-tumor immunity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Peter Moldt
Chief Executive Officer
Randall Schatzman
Chief Financial Officer
William Quinn
Chief Medical Officer
Edith Perez
Vice President
Michael Alonso
Vice President
Nathan Ihle
Vice President
Marcin Kowanetz
Vice President
Brian Safina
VP - Bus. Development
Grant Yonehiro
VP - Engineering
Karla Henning
VP - Manufacturing
Travis Tani
VP - R & D
David Dornan
Browse more venture capital transactions:
Prev: 2/5/2021: Slync venture capital transaction
Next: 2/5/2021: Promenade venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records reported here are derived from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs